GGrantIndex
Sort

64,565 grants matching drug discovery

NEW DRUG TARGETS FOR APOPTOSIS

$1,446,246
University Of Arizona · P01 · FY2005 · CA

Molecular diagnosis and outcome prediction in lymphoma

$1,445,697
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder

$1,445,627
Yan Zhang · Virginia Commonwealth University · UH3 · FY2024 · DA

Center on Intersystem Regulation by Drugs of Abuse

$1,445,477
Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2020 · DA

Development of Brain MRI Contrast Agents

$1,445,351
Alan Koretsky · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment

$1,444,837
D. Martin Watterson · Northwestern University At Chicago · U01 · FY2023 · AG

NMR spectroscopy instrumentation for probing intermolecular interations

$1,444,784
Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · S10 · FY2007 · RR

CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal

$1,444,734
Xincheng Zheng · Oncoimmune, Inc. · R44 · FY2009 · NS

Opioid use disorders: UF Pharmacy medications discovery and development

$1,444,681
Lance R McMahon · University Of Florida · UH3 · FY2021 · DA

Opioid use disorders: UF Pharmacy medications discovery and development

$1,444,681
Christopher R McCurdy · University Of Florida · UH3 · FY2023 · DA

Opioid use disorders: UF Pharmacy medications discovery and development

$1,444,681
Christopher R McCurdy · University Of Florida · UH3 · FY2022 · DA

FAMILIAL PARKINSON'S DISEASE: CLUES TO PATHOGENESIS

$1,444,602
Brigham And Women'S Hospital · P50 · FY2000 · NS

Imaging of Neuropsychiatric Disorders with Developmental and Genetic Mechanisms

$1,444,533
Karen Faith Berman · National Institute Of Mental Health · ZIA · FY2015 · MH

Chemical Countermeasures Collaboration: Chemical Threats Affecting Cellular Respiration

$1,444,424
Office Of The Director, National Institutes Of Health · Y01 · FY2023 · OD

Endocannabinoid Active Sites as Therapeutic Targets

$1,444,077
Alexandros Makriyannis · Northeastern University · P01 · FY2024 · DA

UCLA SPORE in Prostate Cancer

$1,443,180
Robert E Reiter · University Of California Los Angeles · P50 · FY2021 · CA

Narcotic Drug and Opioid Peptide Basic Research Project

$1,442,396
University Of Michigan At Ann Arbor · P50 · FY2001 · DA

Endocannabinoids And Energy Homeostasis

$1,442,319
George Kunos · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA

Center on Membrane Protein Production and Analysis (COMPPAA)

$1,442,059
Wayne A. Hendrickson · New York Structural Biology Center · P41 · FY2017 · GM

UC San Diego Clinical and Translational Research Institute

$1,441,904
Colin A Depp · University Of California, San Diego · KL2 · FY2019 · TR

UC San Diego Clinical and Translational Research Institute

$1,441,904
Colin A Depp · University Of California, San Diego · KL2 · FY2016 · TR

UC San Diego Clinical and Translational Research Institute

$1,441,904
Colin A Depp · University Of California, San Diego · KL2 · FY2018 · TR

Discovery of new cellular targets for small-molecule inhibition of enveloped vir

$1,441,843
Sean P. J. Whelan · Harvard Medical School · U19 · FY2016 · AI

Evolving Hemoproteins for New-to-Nature Ring-Forming Reactions

$1,441,619
Frances H Arnold · California Institute Of Technology · · FY2020 · BIO

Integrated genetic, omic, and immunologic studies to identify endotypes and novel drug targets for asthma and allergic diseases

$1,441,202
Carole Ober · University Of Chicago · U19 · FY2024 · AI